Optimizing Administration of CAR T-Cell Therapy in Multiple Myeloma Through Pharmacist Interventions

Program Description

Despite advances in treatments that have improved survival rates among patients with multiple myeloma (MM), the disease is rarely curable. A large proportion of patients fail to respond to initial therapy or have a short duration of response to treatment. Progression to relapsed/refractory disease in MM presents therapeutic challenges, especially for patients who are triple-refractory to current therapies as well as those who relapse within 12 months of initial therapy. Opportunities for the application of chimeric antigen receptor (CAR) T-cell therapies in the treatment of relapsed/refractory MM is rapidly growing. The successful incorporation of CAR T-cell therapies into the MM treatment paradigm creates clinical and operational challenges that pharmacists and their multidisciplinary teams must address and resolve. In addition to a review of clinical data for use of CAR T-cell therapies in MM, this activity will examine the management of CAR T-cell-related adverse effects and operational strategies for pharmacists to optimize the use of CAR T-cell therapy and improve outcomes for patients. Expert faculty will lead case discussions discerning the role of pharmacists in the clinical and operational management of CAR T-cell therapies for the treatment of patients with MM.

Target audience: Health-system, oncology, and specialty pharmacists

Type of activity: Application
Release date: January 6, 2023
Expiration date: February 29, 2024

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Distinguish the unique properties of chimeric antigen receptor (CAR) T-cell therapies and their current place in the multiple myeloma (MM) treatment paradigm
• Identify strategies for risk assessment and management of CAR T-cell-associated toxicities
• Illustrate best practices and institutional strategies to optimize outcomes for patients with MM treated with CAR T-cell therapy

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-23-006-H01-P. The activity is available for CE credit through February 29, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Katie S. Gatwood, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:

Grant/Research Support: AstraZeneca

Consultant: Sanofi

Speakers Bureau: Jazz Pharmaceuticals, Sanofi, Kite Pharma

Zahra Mahmoudjafari, PharmD, MBA, BCOP, has the following financial relationships with commercial interests to disclose:

Consultant: BMS, Merck, Omeros, Sanofi, Incyte

Speakers Bureau: Omeros

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA, Lauren Assennata; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms